{"name":"Santhera Pharmaceuticals","slug":"santhera-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMGJUNmZYanBuU0k4TlJTTDRxQXk2RHhVVGF2ZjI4UVZwVGJ3LUFGaktSU3VIeXNhT2ZuOHQ5RDJKUHVOUl9NNWlBWXdLbGRIRVV3YU93bndpc05xOUtXdm05ajR1RnlBaUtwa0VuXzcxazZoMlpQbWJwSk5aZkd2bDI3ekNvc0ZyUE9IOXZxNFlCN0oxNmc?oc=5","date":"2026-03-12","type":"pipeline","source":"The Pharma Letter","summary":"Santhera releases full year 2025 trading update - The Pharma Letter","headline":"Santhera releases full year 2025 trading update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOdG8ybnJoZ1BXeUk4ZG9uUGxiRlZIQUVYdjd3djZ1Y1ZoX3hPcHlDMGZsSG9jYmZ1V0R6X29zU1RKdmNuUlpOVEVyQWJZWlVRWFNGUU1SOEstUXJHUGFYa0VTS29DelFRTXdwTXc4T2tOWjRyNS1kaWRzRndXV0IydGlJTWpWTDRoWEFYNTdlMFhGTFdsajR6ZlI4YWNjRHBE?oc=5","date":"2026-03-11","type":"pipeline","source":"Fierce Pharma","summary":"Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales - Fierce Pharma","headline":"Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNaFBaWk40TVM1T1VLc2xEYVdITGJfT3llWWJLdVcxT2s1RXpiTW9CS2RzaDhWSnpXVTNyT2NkdzBhSVFWRWtWVkt4dWJUNjZQX0g4X0QwOUc4WDhfRUlybmpoMVpleXlPei1SaWxSbFZ0S0pQRTlSNk5yUUFqbl9VSzJyeTVnWTRDQnRjQ0pJUnFaZTZhVVZ2SEpsNDRsV0hYYUZ0SmhtdUtGbXV5SkJfT3M2YVNpUEY1UHpEVnlVQV9MRlVyS3FqR2t4alg4bXBvaHlCZ0RiVHBwOEh3b0h4bXNqYmJnVC1GOExlb1ZWMkUxaHEybERIZ2RnbUl4ZkhIVk9SUWc1X1ZuN05ZaVJNU3BqcC1YSWJu?oc=5","date":"2026-02-13","type":"pipeline","source":"Proactive financial news","summary":"Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress - Proactive financial news","headline":"Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQRW1CbVRmOE5zeTluZl95ZE5FRm44enp0SzBRaWZUVFhoNDJha0d4MGM3ODJDZ2ZSTTgzVm5fVXJaSk14OWVReW1YaGN2WkJ0NXRBYWl6ek9XcDE2MHZyVzRmcGhIY184Y2FPQjJFYTlCOERScG5JWXp2N1NYVU1GNkxfSUtXY183WTBRM0U0cFJ5b1JmMVl3a1NzTnhhMFNOaGk5UVIzYU1wVWJpaEs1MFd0eVFJVTVSVVJKOVh2MmtLbU9sRkdFOFZsYw?oc=5","date":"2026-01-09","type":"deal","source":"orrick.com","summary":"Nxera Pharma Licenses Select Asia-Pacific Rights to Vamorolone from Santhera Pharmaceuticals - orrick.com","headline":"Nxera Pharma Licenses Select Asia-Pacific Rights to Vamorolone from Santhera Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQdzR4SzlySnk3MlI4anc1Q3B6MG5rclFQVjZUeEZVcTBKcElNZUh3QVE0NG5XZDAwV1pOdS12QXgxVUt2b1c3V0FxUFhhZTFxUVFGbW1OOEtZVHpnNHZiNUNXNlI1eDlBNEFTZzB1LVBzaThUeTdWTGFvSlZmY2J5czJSaEhfbDVzUGZXcQ?oc=5","date":"2026-01-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"Santhera grants Agamree rights to Nxera for DMD - Pharmaceutical Technology","headline":"Santhera grants Agamree rights to Nxera for DMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNR0dBakU4OURMdmJpZERKS3Z0a1Nfamo3WTV4TDVGTXpDRUlPY0VCRmoxT1pIRXRsUzMzNWdyR3Y2cXBFME1jMG12ZWxjOGh1MXNoNUFxM0p5THRnLTVmZ0c4LWhuNURqaktreE5lMWN1a3UwMUItN2VBSFFuM2Z0ekVfcEI3LTJzV0w2Y25fQTE0UXM5THFrYk9mQjlyN3lkR3dPT3p4MFRueVVndnk3UWFuckdZcE9zVHNSckp5SUxmb3FT?oc=5","date":"2026-01-09","type":"deal","source":"BioSpectrum Asia","summary":"Santhera licenses AGAMREE to Japan's Nxera Pharma in $205 M Asia-Pacific deal - BioSpectrum Asia","headline":"Santhera licenses AGAMREE to Japan's Nxera Pharma in $205 M Asia-Pacific deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxPcFdRc1BLWmtwWmtFS2t4UmZxakdBSGlRc21CRS1RSGYwRXAyLTdVQWppRTM4dzZxYVlRQzVxNVRIVGVTandqeEYwenVyTFFVenJOam1hODlqeF9VQ05sV3VublozMmktNHRPcVNwdm0talcwZEsxLTdtb2dVRFpDS3JkRWc5X0UtTjJjeGdBVVp6aE9EMjV0VFlDcFM1MDN0bTdsNEczSGxNQlI5d3BLMU9KRzR0OF9EWUxGOVY2YjgxTk4tZ1FMbkNKU1J6VC1jTnFUbGFRNDZQUmFaMUJpS3lKTHNNd292NVdLNVYzLWtZaU90OW9OVHpDSE0yTXo4MGJpNmtRRDl5ZnpBNE1kM1BUWmVDM3l2MTdid2JDQ3MzYWgzelZCQi1LOGgzYnE2eU80ZEp2NkFfZzBISVhFRnZWRkpaVl9QekEyZw?oc=5","date":"2026-01-08","type":"deal","source":"globenewswire.com","summary":"Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties - globenewswire.com","headline":"Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxORUdCZVZKTGdMbVJtY0RvS0VUVWxRMi1Td2FPN2VtNy1NUmdHeVh4enJrWEhIUUFTZS1RdU5uYWVRVUxZejhvanNHOER3c1JnNnFidzB4bGFWLXAzVjhhRjBIU1ZYQUZWNWFubnV5a1RjWUFPXzI5OU15V0tJa2NJbGNKTjR2TG8xVko2Z2g3Z2M1ZGJSRHdaQkstWEpJMG5lcU1tTE1OM0dGU2JoRlRFeEdJVmk5Ym5FQjlTbEpSakFaT0NZRGl1ZFBpZ0V4LWJWaVp6R1dGYzN6dWdyY0tmUEdEVjF6NnVFN0tEdzdvd3pONmlySkE?oc=5","date":"2026-01-08","type":"deal","source":"Proactive Investors","summary":"Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug - Proactive Investors","headline":"Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWm1iay1XdWJnd0NWdGNVazU1cWg0ekstbEctZjVqLVVzeGNiUmdhTnZfTzBLUEkxQ3U4cDR1VUczM0pPVzAtZUs1cjZIYjFiQU9xTUMtT2RvdjZyU0k3aWVqOEJUdjZMODZ5cVI1NHhCbEF4WDRhNEJHSkk3aTRwSjVlMWR3bnNHZURB?oc=5","date":"2026-01-07","type":"deal","source":"Yahoo Finance UK","summary":"Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals - Yahoo Finance UK","headline":"Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQY0xZZGk3bDBFRkJqZS03WlpiUkZwUlNFa3JiUTgxU0hBYmdsRHN6enpXMG1UR3NHTnVkRllSZnF1dnhYM1piQVdCUHgwZE9IU0htMTBKWnJBTF9Ha1pLbFM1RVEwRl9XTmswM2pzRktXZHlJazJVdHZSMTQ3MGFzYTlQWGp3NU9Mc0pRcWJvcTJaQVg0MF8yYkgwZjJId281dUNLeFRjVHA0S0xtdVBTbFJJMk0?oc=5","date":"2025-11-04","type":"trial","source":"PharmaTimes","summary":"Santhera reports promising long-term data for AGAMREE in Duchenne muscular dystrophy - PharmaTimes","headline":"Santhera reports promising long-term data for AGAMREE in Duchenne muscular dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE51a19QNm9zXzRUWXByUERSeVgtMzhRMkc0TkVGUndPLTRQX3BXcTdIRXpzQlByTmtINEl3dDZsWjh4N1NaZUNQbThhRDAtMTFjQWgzVHpaZXRHb0ZGcVVRZW8zTXRxRlA4U1B5WlIzc2FUOTl2?oc=5","date":"2025-09-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Santhera and Ikris sign distribution agreement for DMD drug in India - Pharmaceutical Technology","headline":"Santhera and Ikris sign distribution agreement for DMD drug in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQSVBLTTJWYUFTMDZEaXVVNzVoS0FZdlk4bVVVRlI2TXIyUGo3b0hJQWhKTWFlRWlzdUsxb1BjeVh3QmJyaFZZTmVYWm5zMGkyM1FoZVAxV0pWT3F3LTNDcXVDcTdMVHBkNGh2MUxZN25lRGZBZnZaNS12c3hyNnBWc1owazhVSWEzUklxcDJ6SHRiTmZYamNJYnhPdU5aajdDRzlDQVlJRGt1SGpQZkhfSG1R?oc=5","date":"2025-08-29","type":"pipeline","source":"Contract Pharma","summary":"Santhera, Ikris Sign Agreement for Distribution of AGAMREE in India - Contract Pharma","headline":"Santhera, Ikris Sign Agreement for Distribution of AGAMREE in India","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}